Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Inclusion Criteria:

1. Subjects who are diagnosed with type 2 diabetes who have been treated with at leastone hypoglycemic therapy within 12 months prior to screening, with basically stableblood glucose level during screening;

2. During screening period, 120 mmHg ≤ sitting SBP ≤ 160 mmHg and sitting DBP < 110mmHg;

3. Laboratory results before randomization should be: 1) at least twice the result ofUCAR should be 30 mg/g ≤ UACR < 3000mg/g at W-8, W-4, W-2, and W0; 2) EGFR ≥ 45mL/min/1.73 m2 at W-4 and W0; 3) AST and ALT ≤ 2 times the upper limit of normal (ULN), and total bilirubin ≤ 1.5 times ULN at W0; 4) hemoglobin ≥ 90 g/L at W0; 5) 3.5 mmol/L ≤Serum potassium ≤ 4.8 mmol/L at W-4 and W0;

4. Subjects who agree to take effective contraceptive measures with their spousesthroughout the study period and for up to 12 weeks after the last dose;

5. Subjects who thoroughly learn about the nature, significance, possible benefits,possible inconvenience and potential risks of the trial, and understand the studyprocedures and voluntarily sign the informed consent form prior to theirparticipation in the trial.

Exclusion Criteria:

1. Sitting SBP >140 mmHg and/or sitting DBP >90 mmHg at baseline (W0);

2. Color ultrasonography of renal artery indicated renal artery stenosis;

3. ① Acute renal insufficiency② acute nephritic syndrome, polycystic kidney, kidneystone, nephrotic syndrome; ③there is evidence that proteinuria originates fromprimary and secondary renal diseases other than hypertensive renal damage; ④ grosshematuria in the past one year.

4. During the screening/run-in period, major modifications need to be made to thesubject's corresponding treatment regimen due to poor control of other underlyingdiseases based on the investigator's judgement;

5. Subjects with fundus lesions in malignant hypertensive, such as retinal hemorrhageand papilledema;

6. Subjects who need to continuously take glucocorticoids, anti-tumor chemical orbiological agents, and non-steroidal anti-inflammatory drugs during the studyperiod;

7. Subjects with a history of acute myocardial infarction, coronary arteryrevascularization, Class IV heart failure, acute cerebral infarction, cerebralhemorrhage and transient ischemic attack within 3 months prior to randomization;

8. Subjects who have abnormal thyroid function tests with clinically significance;

9. Subjects with poor control of diabetes: HbA1c ≥ 9.0% at W0;

10. Subjects who have undergone major surgery within 3 months prior to screening or needto undergo major surgery during the trial;

11. Subjects whose medication adherence in the run-in period is < 80% or > 120%;

12. Subjects with a history of gastrointestinal surgery that may significantly changethe absorption, distribution, metabolism and excretion of drugs;

13. Subjects who are known to be allergic to renin inhibitors, ARBs, ACEIs and theirexcipients, or those with hypersensitive constitution, or those who experienceserious adverse reactions;

14. Women during pregnancy or lactating;

15. Subjects who need transplantation before randomization and during the trial;

16. Subjects with HIV infection, hepatitis B infection, hepatitis C infection, or otheractive infections;

17. Subjects who have a history of malignant tumor, and those who are suspected ofmalignant tumor;

18. Subjects with a past and current history of mental illness;

19. Subjects with a history of drug abuse or alcohol abuse within 2 years prior toscreening;

20. Subjects who have participated in clinical trials of other drugs/devices as asubject within 3 months prior to screening;

21. Subjects with other diseases or conditions that the investigator considers notsuitable for this trial.